A Phase 3 Study Comparing Elranatamab Alone, Elranatamab with Daratumumab, and Daratumumab/Pomalidomide/Dexamethasone in People with Multiple Myeloma


Full Title

An Open-Label, 3-Arm, Multicenter, Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Elranatamab (PF-06863135) Monotherapy and Elranatamab Plus Daratumumab Versus Daratumumab Plus Pomalidomide plus Dexamethasone in Participants with Relapsed/Refractory Multiple Myeloma Who Have Received at Least 1 Prior Line of Therapy Including Lenalidomide and a Proteasome Inhibitor (WIRB)


Researchers are comparing three different treatments for multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing even after treatment. If you join this study, you will be randomly assigned to get one of these treatments:

  • Elranatamab alone
  • Elranatamab plus daratumumab
  • Pomalidomide, daratumumab, and dexamethasone

Elranatamab and daratumumab are both given as an injection under the skin. Pomalidomide and dexamethasone are both taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have multiple myeloma that keeps growing after at least 1 but no more than 3 prior regimens of treatment.
  • Be able to walk and do routine activities for more than half the time you are awake.
  • Be age 18 or older.


For more information or to see if you can join this study, please call Dr. Alexander Lesokhin’s office at 646-888-5418.




Phase III (phase 3)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID